All In MedTech

FDA Clearance Tracker · P150013-S031

PD-L1 IHC 22C3 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 19, 2026

Approved

Time to decision

234 days

Received Jul 28, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150013-S031
Device name
PD-L1 IHC 22C3 pharmDx
Applicant location
Santa Clara, CA
Received
Jul 28, 2025
Decided
Mar 19, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150013

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval to migrate the PD-L1 IHC 22C3 pharmDx assay using the Autostainer Link 48 for esophageal squamous cell carcinoma (ESCC) with CPS>=10, triple-negative breast cancer (TNBC) with CPS>=10, cervical cancer with CPS>=1, and gastric or gastroesophageal junction (GEJ) adenocarcinoma with CPS>=1 indication to the Dako Omnis automated staining system.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.